Market Overview

Who Ignited The Rally In Sarepta Therapeutics?

Sarepta Says FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C.

Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show.

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading sharply higher by $1.91 at $14.67 in Tuesday's session.

The catalyst for the rally has been an upgrade by Bank of America to a "Buy" rating. Bank of America is making the call ahead of a Q4 earnings report that will be announced on February 26.

The company has beat estimates in each of its previous three quarters, but shortfall in revenues in two of three quarters has exerted selling pressure on the issue.

Related Link: 1 Amgen-FDA Story To Keep An Eye On

Prior the upgrade, the issue had been mirrored in a consolidation period over the past month between its year low ($11.33) and $13.00. On the heels of the upgrade, traders took the issue all the way to $14.45 before finding willing sellers.

That puts the issue at its highest level since January 19, when it peaked at $14.74 and ended the session at $13.95.

Posted-In: Pre-market outlookTechnicals Intraday Update Movers Trading Ideas


Related Articles (SRPT)

View Comments and Join the Discussion!